Скачать или смотреть PneumoSIP System (English Version)

ADVANTAGES
The PneumoSIP System combines a one-stop diagnostic platform and an amplification-based test to provide a fast, accurate, simple and cost-efficient solution for the diagnosis of Pneumonia.
WHY PNEUMONIA?
Community-acquired pneumonia (CAP), together with lower respiratory tract infections, is the fourth most common cause of death in adults (reaching 90% in people over 65) and the leading cause of death in children under 5 years. The annual incidence of CAP in Europe is expected to be around 3,4 million cases and it represents an important burden on healthcare resources. The associated annual cost in Europe is estimated to be 10€ billion, mainly due to hospitalisation of late diagnosed patients.
EARLY DIAGNOSTIC IS KEY
Late Diagnostic is one of the main causes of patient deterioration. PneumoSIP surpasses the existing methods by reducing time-to-result and provides information about the best line of treatment.
PNEUMOSIP IS AN EU-ENDORSED PRODUCT
AlphaSIP is a winner of the 2015 European Commission’s SME Instrument, which promotes the development of Europe’s best and most innovative SMEs. This novel funding scheme helps high-potential SMEs to develop groundbreaking innovative ideas for products, services or processes that are ready to face global market competition. The SME Instrument has opened new possibilities for AlphaSIP, greatly accelerating the development of our new product range and increasing our chances of succeeding in the medical market.

Thanks to this award, AlphaSIP will receive 3,4M € to complete the development of PneumoSIP, our amplification-based pneumonia kit and MultiSIP, its associated one-stop diagnostic platform. The development phase is expected to end in 24 months, after clinical validation, making both elements ready for commercialization.

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 685052